Pharmacokinetic interactions between theophylline and prulifloxacin in healthy volunteers

Clinical Drug Investigation

Volumn 16, Issue 5, 1998, Pages 387-392

  Fattore, C ^a   Cipolla, G ^a   Gatti, G ^a   Bartoli, A ^a   Orticelli, G ^b   Picollo, R ^b   Millerioux, L ^c   Ciottoli, G B ^b   Perucca, E ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b Piazzale della Stazione SNC   (Italy)

^c Cephac Research Centre   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BRONCHODILATING AGENT; CYTOCHROME P450; PRULIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THEOPHYLLINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; DRUG OXIDATION; ENZYME INHIBITION; EPIGASTRIC PAIN; FATIGUE; FEMALE; HEADACHE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TACHYCARDIA; TREMOR;

EID: 0031760244     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199816050-00006     Document Type: Article

References (18)

1. Segawa J, Kitano M, Kazuno K, et al. Studies on pyridonecarboxylic acids. 1. Synthesis and antibacterial evaluation of 7-substituted-6-halo-4-oxo-(1,3)thiazeto(3,2-a)quinoline-3-carboxylic acids. J Med Chem 1992; 35: 4727-38
2. Nakashima M, Uematsu T, Kosuge K, et al. Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers. J Clin Pharmacol 1994; 34: 930-7
3. Ozaki M, Matsuda M, Tommi Y, et al. In vitro antibacterial activity of a new quinolone, NM394. Antimicrob Agents Chemother 1991; 35: 2490-5
4. Ozaki M, Matsuda M, Tommi Y, et al. In vivo evaluation of NM441, a new thiazeto quinoline derivative. Antimicrob Agents Chemother 1991; 35: 2496-9
5. Yoshida T, Mitsuhashi S. Antibacterial activity of NM394, the active prodrug MN441, a new quinolone. Antimicrob Agents Chemother 1993; 37: 793-800
6. Kobayashi H, Kawai S, Sakayori S, et al. Dose finding study on NM441 in chronic respiratory tract infections. Jpn J Chemother 1996; 44 Suppl. 1: 362-78
7. Kumazawa J, Matsumoto T, Kumamoto Y, et al. Clinical dose finding study on NM441 in complicated urinary tract infections. Jpn J Chemother 1996; 44 Suppl. 1: 451-61
8. Fuhr U, Anders EM, Mahr G, et al. Inhibitory potency of quinolone antibacterial agents on cytochrome P4501A2 activity in vivo and in vitro. Antimicrob Agents Chemother 1992; 36: 942-8
9. Fuhr U, Strobl G, Manaut F, et al. Quinolone antibacterial agents - relationship between structure and in vitro inhibition of the human cytochrome P450 isoform 1A2. Mol Pharmacol 1993; 43: 191-9
10. Wanogho E, Burke MD. Fluoroquinolone inhibition of cytochrome P450. Br J Clin Pharmacol 1993; 36: 168P
11. Edwards DJ, Bowles SK, Sensson CK, et al. Inhibition of drug metabolism by quinolone antibiotics. Clin Pharmacokinet 1988; 15: 194-204
12. Radandt JM, Randall MC, Dudley MN. Interaction of fluoroquinolones with other drugs: mechanisms, variability, clinical significance and management. Clin Infect Dis 1992; 14: 272-84
13. Upton RA. Pharmacokinetic interactions between theophylline and other medications. Clin Pharmacokinet 1991; 20 (Pt 1): 66-80
14. Wijnands WJA, Van Herwaarden CLA, Vree TB. Enoxacin raises plasma theophylline concentrations. Lancet 1984; II: 108-9
15. Nakabayashi M, Hashiguchi K, Miyashita N, et al. Effect of NM441 on serum concentration of theophylline. Jpn J Chemother 1996; 44 Suppl. 1: 233-7
16. Niki Y. Quinolone antimicrobial agents and theophylline. Chest 1992; 101: 881
17. Niki Y, Hashiguchi K, Kimura M, et al. Quinolone antibacterial agents and blood concentration of theophylline. Classification based on extent of drug interaction. Chemotherapy 1992; 40: 598-601
18. Sorgel F, Mahr G, Granneman GR, et al. Effect of 2-quinolone antibacterials, temafloxacin and enoxacin, on theophylline pharmacokinetics. Clin Pharmacokinet 1992; 22 Suppl. 1: 65-74